Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC’s ‘Final Trades’
On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named ConocoPhillips, and Rob Sechan suggested AbbVie, with all four stocks having recent news and price changes.
Looking Into AbbVie’s Recent Short Interest
AbbVie’s (NYSE:ABBV) short percent of float has risen 3.33% since its last report. The company recently reported that…
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Comparative Study: AbbVie And Industry Competitors In Biotechnology Industry
In today’s fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct…
Goldman Sachs Optimistic About Regenxbio’s Gene Therapy Pipeline, Sees Over 160% Upside
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
AbbVie’s Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance patient access and incentivize development.
AbbVie, Amazon, Goldman Sachs And 2 Major Health Care Stocks On CNBC’s ‘Final Trades’
AbbVie Inc. has good dividend yield and attractive valuations, according to Jim Lebenthal of Cerity Partners.
AbbVie’s Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients
AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a 51.9% objective response rate.